Literature DB >> 21906785

Hyperhomocysteinemia and the presence of cardiovascular disease are associated with kynurenic acid levels and carotid atherosclerosis in patients undergoing continuous ambulatory peritoneal dialysis.

Krystyna Pawlak1, Michal Mysliwiec, Dariusz Pawlak.   

Abstract

INTRODUCTION: Hyperhomocysteinemia and the activation of kynurenine (KYN) pathway have been reported as the factors participated in atherosclerosis in uraemic patients. The objective of this study was to verify whether hyperhomocysteinemia may be involved in atherosclerotic cardiovascular disease (CVD) in patients undergoing continuous ambulatory peritoneal dialysis (CAPD).
MATERIALS AND METHODS: We determined the plasma concentrations of KYN, KYNA, KYNA/KYN ratio, homocysteine (Hcy) and intima-media thickness (IMT) - an early reflection of the systemic atherosclerosis in CAPD patients both with and without CVD and healthy controls.
RESULTS: KYNA concentrations and KYNA/KYN ratio were about 3 times higher in the patients with hyperhomocysteinemia (Hcy>15μM) compared to those with normal Hcy levels (<15μM), and they were significantly lower in CVD[+] than in CVD[-] patients in these studied groups. The presence of CVD was associated with higher Hcy levels only in the patients with Hcy>15μM. The positive association was between Hcy and KYNA, KYNA/KYN ratio in all CAPD patients and in CVD[+] patients with hyperhomocysteinemia. IMT was positively associated with Hcy levels in patients with hyperhomocysteinemia, whereas there was no relationship between IMT and KYNA concentrations in the studied groups.
CONCLUSIONS: These results showed the association between hyperhomocysteinemia and carotid atherosclerosis as well as the possible role of hyperhomocysteinemia in the activation of KYNA production in CAPD patients. The elevated KYNA levels observed in patients with hyperhomocysteinemia seem to be protective against Hcy-mediated atherosclerosis in these patients.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21906785     DOI: 10.1016/j.thromres.2011.08.016

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  7 in total

Review 1.  Tryptophan-kynurenine pathway is dysregulated in inflammation, and immune activation.

Authors:  Qiongxin Wang; Danxia Liu; Ping Song; Ming-Hui Zou
Journal:  Front Biosci (Landmark Ed)       Date:  2015-06-01

Review 2.  Oxidative Storm Induced by Tryptophan Metabolites: Missing Link between Atherosclerosis and Chronic Kidney Disease.

Authors:  Iwona Kwiatkowska; Justyna M Hermanowicz; Michal Mysliwiec; Dariusz Pawlak
Journal:  Oxid Med Cell Longev       Date:  2020-12-29       Impact factor: 6.543

Review 3.  Kynurenine pathway in kidney diseases.

Authors:  Izabela Zakrocka; Wojciech Załuska
Journal:  Pharmacol Rep       Date:  2021-10-06       Impact factor: 3.919

Review 4.  Kynurenine Pathway in Chronic Kidney Disease: What's Old, What's New, and What's Next?

Authors:  Adrian Mor; Bartlomiej Kalaska; Dariusz Pawlak
Journal:  Int J Tryptophan Res       Date:  2020-09-21

Review 5.  Kynurenine Pathway Metabolites as Potential Clinical Biomarkers in Coronary Artery Disease.

Authors:  Renáta Gáspár; Dóra Halmi; Virág Demján; Róbert Berkecz; Márton Pipicz; Tamás Csont
Journal:  Front Immunol       Date:  2022-02-08       Impact factor: 7.561

6.  Aortic stiffness-Is kynurenic acid a novel marker? Cross-sectional study in patients with persistent atrial fibrillation.

Authors:  Tomasz Zapolski; Anna Kamińska; Tomasz Kocki; Andrzej Wysokiński; Ewa M Urbanska
Journal:  PLoS One       Date:  2020-07-31       Impact factor: 3.240

7.  Expression of the C677T Polymorphism of the 5, 10-Methylenetetrahydrofolate Reductase (MTHFR) Gene in Patients with Carotid Artery Atherosclerosis.

Authors:  Anying Li; Wei Huang; Qiong Yang; Liping Peng; Qiang Liu
Journal:  Med Sci Monit       Date:  2020-07-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.